Mutant KRAS is a druggable target for pancreatic cancer

Pancreatic ductal adenocarcinoma (PDA) represents an unmet therapeutic challenge. PDA is addicted to the activity of the mutated KRAS oncogene which is considered so far an undruggable therapeutic target. We propose an approach to target KRAS effectively in patients using RNA interference. To meet t...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Zorde Khvalevsky, Elina, Gabai, Racheli, Rachmut, Itzhak Haim, Horwitz, Elad, Brunschwig, Zivia, Orbach, Ariel, Shemi, Adva, Golan, Talia, Domb, Abraham J., Yavin, Eylon, Giladi, Hilla, Rivkin, Ludmila, Simerzin, Alina, Eliakim, Rami, Khalaileh, Abed, Hubert, Ayala, Lahav, Maor, Kopelman, Yael, Goldin, Eran, Dancour, Alan, Hants, Yael, Arbel-Alon, Sagit, Abramovitch, Rinat, Shemi, Amotz, Galun, Eithan
פורמט: Artigo
שפה:Inglês
יצא לאור: National Academy of Sciences 2013
נושאים:
Biological Sciences
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3870687/
https://ncbi.nlm.nih.gov/pubmed/24297898
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1314307110
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים